Loading...
XNAS
OCEAW
Market cap1mUSD
Jun 06, Last price  
0.01USD
1D
52.43%
1Q
-57.99%
IPO
-97.91%
Name

Ocean Biomedical Inc

Chart & Performance

D1W1MN
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
Rev. gr., 5y
%
Revenues
0k
Net income
-3m
L
-232,000-1,653,000-62,344,000565,470-3,301,000
CFO
-4m
L-55.67%
0-64,000-1,053,000-747,297-9,429,000-4,180,000

Profile

Ocean Biomedical, Inc., a biopharmaceutical company, focuses on discovering and developing therapeutic products in oncology, fibrosis, infectious diseases, and inflammation. The company is developing mono-specific and bi-specific humanized monoclonal antibodies (mAb) product candidates targeting Chi3l1 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome. It is also developing three product candidates based on the WPDS platform, including a malaria vaccine candidate; a humanized mAb malaria therapeutic candidate targeting Plasmodium falciparum glutamic-acid-rich protein (PfGARP); and a small molecule malaria therapeutic candidate targeting PfGARP, as well as a product candidate for the treatment of COVID-19 in hospitalized patients. The company was incorporated in 2019 and is based in Providence, Rhode Island.
IPO date
Sep 15, 2021
Employees
9
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑12
Income
Revenues
Cost of revenue
3,798
Unusual Expense (Income)
NOPBT
(3,798)
NOPBT Margin
Operating Taxes
(1,524)
Tax Rate
NOPAT
(3,798)
1,524
Net income
(3,301)
 
565
-100.91%
Dividends
Dividend yield
Proceeds from repurchase of equity
(48,514)
BB yield
Debt
Debt current
16,300
12,118
2,150
Long-term debt
Deferred revenue
3,150
Other long-term liabilities
64,629
66,252
Net debt
16,300
8,722
(108,622)
Cash flow
Cash from operating activities
(4,180)
(9,429)
(747)
CAPEX
Cash from investing activities
(2,100)
Cash from financing activities
3,400
10,399
2,100
FCF
(2,806)
14,939
(3,837)
Balance
Cash
4
328
Long term investments
3,392
110,443
Excess cash
3,396
110,772
Stockholders' equity
(205,535)
(196,055)
107,678
Invested Capital
188,848
183,662
1,920
ROIC
ROCE
22.76%
EV
Common stock shares outstanding
27,503
13,225
Price
0.55
-16.21%
0.66
-93.65%
10.40
4.10%
Market cap
15,209
 
137,540
4.10%
EV
31,509
28,918
EBITDA
(3,798)
EV/EBITDA
Interest
2,046
691
Interest/NOPBT